Xencor Inc. (NASDAQ:XNCR)’s share price traded down 2.7% on Wednesday . The stock traded as low as $23.69 and last traded at $24.05, with a volume of 108,480 shares trading hands. The stock had previously closed at $24.71.

Several equities analysts recently weighed in on the stock. Wedbush reaffirmed an “outperform” rating and set a $27.00 target price on shares of Xencor in a research note on Tuesday, June 28th. Leerink Swann reaffirmed an “outperform” rating and set a $18.00 target price on shares of Xencor in a research note on Wednesday, June 29th. Canaccord Genuity reaffirmed a “buy” rating on shares of Xencor in a research note on Tuesday, June 28th. Finally, Zacks Investment Research cut shares of Xencor from a “buy” rating to a “hold” rating in a research note on Wednesday, August 31st. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Xencor presently has an average rating of “Buy” and a consensus target price of $23.50.

The firm has a market capitalization of $1.01 billion, a price-to-earnings ratio of 26.29 and a beta of 2.14. The company’s 50-day moving average is $21.88 and its 200-day moving average is $16.33.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/xencor-inc-xncr-stock-price-down-2-7.html

Xencor (NASDAQ:XNCR) last released its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $1.31. Xencor had a net margin of 39.07% and a return on equity of 22.53%. The business earned $66 million during the quarter, compared to analyst estimates of $7.43 million. Equities research analysts forecast that Xencor Inc. will post $0.72 EPS for the current fiscal year.

In related news, insider Edgardo Baracchini, Jr. sold 2,500 shares of the company’s stock in a transaction dated Wednesday, August 10th. The shares were sold at an average price of $21.83, for a total value of $54,575.00. Following the completion of the sale, the insider now owns 2,500 shares of the company’s stock, valued at $54,575. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder John S. Stafford III sold 30,500 shares of the company’s stock in a transaction dated Thursday, August 11th. The shares were sold at an average price of $21.87, for a total transaction of $667,035.00. Following the completion of the sale, the insider now directly owns 7,500 shares of the company’s stock, valued at approximately $164,025. The disclosure for this sale can be found here. 4.03% of the stock is currently owned by corporate insiders.

Large investors have recently made changes to their positions in the stock. Deerfield Management Co. boosted its position in Xencor by 175.9% in the first quarter. Deerfield Management Co. now owns 3,467,512 shares of the biopharmaceutical company’s stock worth $46,534,000 after buying an additional 2,210,900 shares during the last quarter. Primecap Management Co. CA boosted its position in Xencor by 30.8% in the first quarter. Primecap Management Co. CA now owns 4,731,995 shares of the biopharmaceutical company’s stock worth $63,503,000 after buying an additional 1,115,081 shares during the last quarter. Oxford Asset Management boosted its position in Xencor by 300.6% in the second quarter. Oxford Asset Management now owns 367,101 shares of the biopharmaceutical company’s stock worth $6,971,000 after buying an additional 275,470 shares during the last quarter. Vanguard Group Inc. boosted its position in Xencor by 17.3% in the second quarter. Vanguard Group Inc. now owns 1,343,701 shares of the biopharmaceutical company’s stock worth $25,517,000 after buying an additional 197,814 shares during the last quarter. Finally, Teachers Advisors Inc. boosted its position in Xencor by 371.0% in the second quarter. Teachers Advisors Inc. now owns 194,443 shares of the biopharmaceutical company’s stock worth $3,692,000 after buying an additional 153,158 shares during the last quarter. 67.72% of the stock is owned by hedge funds and other institutional investors.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. Its segment is related to the development of pharmaceutical products. It uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions.

5 Day Chart for NASDAQ:XNCR

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.